EP0722313B1 - Viscoelastic compositions of fluorinated organic compounds - Google Patents

Viscoelastic compositions of fluorinated organic compounds Download PDF

Info

Publication number
EP0722313B1
EP0722313B1 EP94929508A EP94929508A EP0722313B1 EP 0722313 B1 EP0722313 B1 EP 0722313B1 EP 94929508 A EP94929508 A EP 94929508A EP 94929508 A EP94929508 A EP 94929508A EP 0722313 B1 EP0722313 B1 EP 0722313B1
Authority
EP
European Patent Office
Prior art keywords
composition according
surfactant
composition
compound
gel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP94929508A
Other languages
German (de)
French (fr)
Other versions
EP0722313A1 (en
Inventor
Marie-Pierre Krafft
Jean G. Riess
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alliance Pharmaceutical Corp
Original Assignee
Alliance Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alliance Pharmaceutical Corp filed Critical Alliance Pharmaceutical Corp
Publication of EP0722313A1 publication Critical patent/EP0722313A1/en
Application granted granted Critical
Publication of EP0722313B1 publication Critical patent/EP0722313B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A61K31/025—Halogenated hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A61K8/042—Gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/69—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing fluorine
    • A61K8/70—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing fluorine containing perfluoro groups, e.g. perfluoroethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0026—Blood substitute; Oxygen transporting formulations; Plasma extender
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations

Definitions

  • the present invention relates to viscoelastic compositions or gels which may have uses in cosmetics, biology, therapeutics and elsewhere, eg as protective creams and lubricating agents. It relates particularly to viscoelastic compositions that have high concentrations of highly fluorinated or perfluorinated compounds.
  • Fluorocarbons have numerous biomedical applications because of their high chemical and biological inertness and their capacity to dissolve a considerable amount of gases, particularly oxygen, carbon dioxide and air per unit volume. Indeed, at 37°C under a pure oxygen atmosphere, a fluorocarbon can dissolve about 50% of its volume of oxygen.
  • compositions of fluorocarbons can also be used for the treatment of wounds, for example burns, as described in U.S. Patent 4,366,169.
  • the wound is put in contact with a liquid fluorocarbon directly, or indirectly through a dressing, for example a sponge, gauze, foam, dispersion or gel into which the fluorocarbon has been incorporated.
  • a dressing for example a sponge, gauze, foam, dispersion or gel into which the fluorocarbon has been incorporated.
  • the '169 patent does not disclose a high concentration fluorocarbon formulation or a procedure for preparing a fluorocarbon-rich gel.
  • High concentration fluorocarbon formulations can increase the gas-transfer capacity of preparations for topical application, improving their therapeutic effects and protecting the tissues coated therewith. Highly viscous preparations of this type can be easily applied to the wounded tissues.
  • Fluorocarbons have been used in the form of emulsions or water-rich gels.
  • Known gel formulations contain low concentrations of fluorocarbons and require stabilizing or thickening agents to maintain a desirable consistency.
  • U.S. Patent No. 5,073,378 describes compositions for the treatment of burns, obtained from solutions of collagen, containing a growth-factor derived from platelets, and a fluorocarbon phase whose perfluorocarbon content is low.
  • U.S. Patent No. 4,917,930 and EP-A-0158996 describe compositions in the form of fluorocarbon emulsions comprising no more than 50% fluorocarbon by weight, or about 25% fluorocarbon by volume.
  • compositions are obtained by preparing an initial dispersion comprising a fluorocarbon and a surfactant complexed with the fluorocarbon, and then concentrating the fluorocarbon phase of the dispersion, for example by centrifugation, separating the fluorocarbon-rich phase, and redispersing this phase in an aqueous medium optionally containing a surfactant.
  • this procedure makes it possible to limit the quantity of surfactant used, it does not provide formulations having fluorocarbon concentrations greater than 50% by weight.
  • the emulsions obtained by this process are intended to be injectable.
  • U.S. Patent No. 4,569,784 describes a stable gel of fluorocarbon also comprising no more than 50% by volume of fluorocarbon, which requires considerable quantities of surfactant for stabilization.
  • This gel is prepared by a similar complex procedure of concentrating an emulsion by centrifugation, and requires high-pressure apparatus or the use of ultrasound.
  • FR-A-2 630 347 describes fluorocarbon gels comprising, by contrast with those described in the above patents, a high proportion of water, about 60 to 98% by weight.
  • WO-A-93/09762 describes the use of fluorocarbon suspensions or emulsions for intravascular applications, containing at most 90 g/100 ml (about 50% v/v).
  • WO-A-90/15807 describes the use of phosphorus-containing fluorinated surfactants in fluorocarbon emulsions and other compositions containing at most 70% in volume of fluorocarbons.
  • Obraztsov (poster contribution to the fifth ISBS, San Diego California, USA, March 1993) describes an emulsion prepared from a mixture of fluorocarbons containing perfluorodecalin (80% w/v, 40% v/v), emulsified using a polyoxyethylene/polyoxypropylene copolymer (Proxanol 268) and gelified by 1,2-propyleneglycol.
  • a polyoxyethylene/polyoxypropylene copolymer Proxanol 268
  • gelified by 1,2-propyleneglycol 1,2-propyleneglycol.
  • Preliminary studies have shown that this emulsion has a beneficial effect on the speed of cicatrization of burns and surgical wounds (activation of keratinocytes) and should be more efficacious than the biostimulating medicaments traditionally used (methyluracyl and solkoseryl).
  • the fluorocarbon content of these preparations does not exceed 50% by volume and the gelification is obtained by
  • the invention provides a viscoelastic gel composition having an oily phase and an aqueous phase, wherein:
  • Embodiments of the present invention may provide compositions comprising highly fluorinated or perfluorinated organic compounds formulated as gels having highly viscoelastic properties. They also provide procedures to gelify fluorocarbon. Certain of these compositions are perfectly transparent. Embodiments may be useful in many applications, but particularly in medicine, pharmacy, cosmetics and in biological applications.
  • Preferred compositions having a higher fluorocarbon concentration than previously known compositions of the same type, are advantageously used as topical applications.
  • Preferred compositions are stable, easily sterilized by heat, and are easy to prepare without requiring thickening by addition of a gelifying agent.
  • They may be in the form of a viscoelastic gel, stable and permeable to gases.
  • the fluorinated organic compound can be chosen, for example, among the fluorocarbons and perfluorinated compounds such as linear, branched, cyclic or polycyclic perfluoroalkanes, perfluoroethers, perfluoropolyethers, perfluoroamines, freons, mixed fluorinated/hydrogenated compounds, perfluoroalkyl bromides or chlorides and mixed derivatives, which can be partially fluorinated and partially hydrogenated.
  • fluorocarbons and perfluorinated compounds such as linear, branched, cyclic or polycyclic perfluoroalkanes, perfluoroethers, perfluoropolyethers, perfluoroamines, freons, mixed fluorinated/hydrogenated compounds, perfluoroalkyl bromides or chlorides and mixed derivatives, which can be partially fluorinated and partially hydrogenated.
  • Suitable compounds are perfluorodecalin, 1,2-bis(F-alkyl)ethenes (1,2-bis(F-butyl)ethene, 1-F-isopropyl,2-F-hexylethene and 1,2-bis(F-hexyl)ethene), perfluoromethyldecalin, perfluorodimethyldecalin, perfluoromethyl-, and dimethyladamantane, perfluoromethyl-dimethyl- and trimethylbicyclo (3,3,1) nonane and homologs, perfluoroperhydrophenanthrene, ethers of formulae: (CF 3 ) 2 CFO(CF 2 CF 2 ) 2 OCF(CF 3 ) 2 , (CF 3 ) 2 CFO(CF 2 CF 2 ) 3 OCF(CF 3 ) 2 , (CF 3 ) 2 CFO(CF 2 CF 2 ) 2 F, (CF 3 ) 2 CFO(CF 2 CF 2 ) 3 F, F[CF(
  • the highly fluorinated or perfluorinated compound used comprises from 2 to 20 carbon atoms, preferably from 6 to 20 carbon atoms and more preferably from 8 to 20 carbon atoms.
  • the highly fluorinated or perfluorinated compound of the composition has a high boiling point, for example above 140°C, so that its evaporation is slow and it is well adapted to use in the form of a salve or ointment.
  • a fluorocarbon having a lower boiling point can be used.
  • the surfactants used in the invention can be perfluoroalkylated surfactants alone or in mixtures with one or more hydrogenated surfactants.
  • perfluoroalkylated is meant that the surfactant contains a perfluoroalkyl group. Preferably it also contains a (non-fluorinated) alkyl group.
  • the surfactants can be non-ionic, anionic, cationic or zwitterionic or mixtures thereof.
  • surfactants known by those skilled in the art to be the most biocompatible are used. Accordingly, perfluoroalkylated surfactants are preferred, as they are much more efficacious and less toxic than their hydrocarbon analogs, particularly because they have low hemolytic activity (J.G. Riess et al, Adv. Mat., 3:249-251 (1991).
  • compounds of formula I detailed hereafter tolerated at doses up to 1.25g/kg after intravenous injection in mice of a dispersion of these compounds in physiological saline.
  • Compounds of WO-A-91/914689, telomeric amphiphilic surfactants, used in this invention are tolerated up to 4g/kg after intravenous injection in mice of a dispersion of these compounds in physiological saline.
  • Suitable perfluoroalkylated surfactants are the amine oxides described in U.S.Patent 3,828,085, in particular those having the formula R F (CH 2 ) n CONH-R 1- N(O)R 2 R 3 ("formula I") wherein
  • the quantities of surfactants used in the invention are low (0.1 to 10% w/v) and are chosen in relation with the quantity of aqueous phase used such that the weight ratio of surfactant/aqueous phase is from 1/10 to 1/1, preferably from 1/5 to 1/3.
  • compositions of the invention can be prepared by low-energy mechanical homogenization techniques, in particular, which are far easier to operate than those such as sonication or high-energy homogenization formerly used for the preparation of fluorocarbon gels.
  • the invention provides a procedure for the preparation of the composition of fluorinated organic compounds described above, comprising the steps of:
  • the degassing can be done for example, by centrifugation at room temperature.
  • the gel can be sterilized; this can be done, for example, by heating in a static autoclave under standard procedures.
  • the composition comprises additives
  • additives these can be added to the aqueous phase, the oily phase or to both phases.
  • the additives can be mineral salts, buffers, oncotic and osmotic agents, nutritive agents, active principles, medicinal substances, filters of particular rays, or other ingredients that improve the stability, efficacy and biological tolerance of the compositions.
  • compositions of fluorinated compounds of the invention present characteristics very different from those of known emulsions and fluorocarbon gels.
  • the gels compositions of the invention are often in the form of transparent gels, as compared to the milky emulsions.
  • concentration of perfluorinated compound of the present gel compositions is far higher (75 to 99.7% v/v) than the maximum concentration of up to about 70% (v/v) in known compositions, and the ratio of surfactant to the highly fluorinated or perfluorinated compounds, necessary for the preparation of the composition, is far lower than that used in known compositions.
  • the quantity of water which can be incorporated in the gel is variable and can be adapted to the intended application. Indeed, some compositions may contain only 0.3% of water, but others may contain up to 25% (v/v) of water. In the latter case, greater quantities of surfactant are generally used, because for a given concentration of surfactant, the viscosity of the gel is decreased as the quantity of water increases. For a given amount of water, the viscosity can be increased by increasing the proportion of surfactant. A surfactant to aqueous phase ratio of 1/5 generally provides a satisfactory viscosity for many uses.
  • the preparation of the gels of the invention does not require the addition of a gelifying agent, and these gels can be sterilized by heat under standard conditions, and stored for several months at room temperature, without apparent degradation.
  • compositions of highly fluorinated or perfluorinated compounds of the invention can find numerous applications, in particular in cosmetics and pharmacy as well as in light radiation protective or other barrier creams. Their use in ophthalmology is also contemplated. They can also be used in cutaneous applications for the healing of wounds, burns, and bruises, and for the reduction of hypertrophic scars. Indeed, highly fluorinated or perfluorinated compounds, being both hydrophobic and lipophobic, have the property, when spread over the skin (the wound), of isolating the skin and forming a barrier to all forms of contamination and to dust, while remaining permeable to gas and particularly to oxygen.
  • An efficacious protection can also be obtained with thin films of gel of highly fluorinated or perfluorinated compounds.
  • these gels can also contain medicaments, for example growth-factors, antibiotics, nutritive elements or other beneficial substances, for example hydrating agents, which will thus be delivered at the appropriate site.
  • medicaments for example growth-factors, antibiotics, nutritive elements or other beneficial substances, for example hydrating agents, which will thus be delivered at the appropriate site.
  • the gels of highly fluorinated or perfluorinated compounds have in addition lubricating properties, improving the slipperiness and reducing friction.
  • compositions of the invention can also be used to realize more complex formulations permitting the simultaneous delivery of hydrophilic and lipophilic drugs.
  • compositions of the invention can also be incorporated into a dressing to be applied on the skin.
  • dressing here includes any medical material destined to maintain the gel in contact with the skin and perhaps to apply pressure, for topical treatments in the biomedical or cosmetic field.
  • the gels can be incorporated into or deposited on various supports for other applications.
  • compositions of the invention can also be used in any application related to the particular properties of the compositions and in particular to their highly viscoelastic character, their transparency, their surface active character, their chemical inertness, their permeability to oxygen, and if necessary to those of other additives present in the composition.
  • pentadecafluoroheptylamidopropyl -dimethylamine oxide (F7AO) is used as a surfactant.
  • F7AO pentadecafluoroheptylamidopropyl -dimethylamine oxide
  • a high proportion of fluorocarbon (99% v/v) was used.
  • the surfactant F7AO (0.045g, 0.2% w/v) was dispersed by mechanical stirring in water for injectable preparations (0.225g, 1% v/v) at a temperature of 20 to 30°C.
  • a quantity of 22.28ml of perfluorodiisopropyldecalin (44.55g, 99% v/v) was then added under a flow of nitrogen at 20-30°C, while stirring with a mixer, and the stirring was continued for 10 min.
  • the gel thus obtained was degassed by centrifugation at 1000 rpm for 15 min at room temperature, then conditioned in 5 ml flasks and sterilized in a static autoclave at 121°C for 15 min under a pressure of 10 5 Pa (10 5 N/m 2 ).
  • the viscosity of the gel at 25°C was determined with a Bohlin CS rheometer (3 ml cells).
  • Example 2 The procedure described in Example 1 was followed to prepare a fluorocarbon gel composition, using 0.112g of surfactant F7AO, 0.562g of injectable water and 21.94ml (43.88g) of perfluorodiisopropyldecalin. A gel containing 97.5% v/v of fluorocarbon, 2.5% v/v of water and 0.5% w/v of surfactant was thus obtained. The composition and viscosity of the gel are shown in Table I.
  • Example 1 The procedure described in Example 1 was followed starting with 0.225g of surfactant F7AO, 1.125g of injectable water and 21.37ml (42.75g) of perfluorodiisopropyldecalin.
  • the composition and viscosity of the gel are shown in Table I.
  • Example 2 The procedure described in Example 1 was followed to prepare a gel using 0.187g of surfactant F7AO, 0.560g of injectable water and 21.94ml (43.88g) of perfluorodiisopropyldecalin.
  • composition and viscosity of the gel are shown in Table I.
  • Example 1 The procedure described in Example 1 was followed starting with 0.750g (3.33% w/v) of F7AO, 2.25g (10% v/v) of injectable water and 20.25ml (40.50g, 90% v/v) of perfluorodiisopropyldecalin.
  • composition and viscosity of the gel are shown in Table I.
  • Example 1 The procedure described in Example 1 was followed starting with 0.9g (4% w/v) of F7AO, 4.5g (20% w/v) of injectable water and 18.00ml (20% v/v) of perfluorodiisopropyldecalin.
  • the composition and viscosity of the gel are shown in Table I.
  • Example 2 The procedure described in Example 1 was followed starting with 0.023 g of F7AO (0.1% w/v), 0.12 g of injectable water (0,1% v/v), and 22.3 ml (99.5% v/v) of perfluorodiisopropyldecalin.
  • composition and viscosity of the gel are shown in Table I. No modification in the appearance of the gel was seen after one year of storage at room temperature.
  • a low viscosity gel of perfluoroperhydrophenanthrene* and perfluoro n-butyldecalin at a combined concentration of 90% in volume was prepared following the procedure described in Example 1 but using the following components:
  • composition and viscosity of the gel are shown in Table I. No change in the appearance of the gel obtained in was seen after one year of storage at room temperature.
  • Example 1 The procedure described in Example 1 was followed to prepare a fluorocarbon gel, but using as fluorocarbon APF-260TM, i.e. a mixture of perfluorodixylylmethane and perfluorodixylylethane.
  • fluorocarbon APF-260TM i.e. a mixture of perfluorodixylylmethane and perfluorodixylylethane.
  • composition and viscosity of the gel are shown in Table I.
  • Example 1 The procedure of Example 1 was used. In addition the mixed fluorocarbon/hydrocarbon compound C 6 F 13 C 10 H 21 was dispersed with F7A0 in water.
  • the gel is stable for at least one year.
  • Example 2 The procedure described in Example 1 was followed to prepare a gel of perfluorodecalin, using the following components:
  • composition and viscosity of the gel are shown in Table I.
  • a gel of perfluorooctyl bromide was prepared, following the same operation procedure as in Example 1, but using the following components:
  • composition and viscosity of the gel are shown in Table I.
  • composition and viscosity of the gel are shown in Table I.
  • Example 2 The procedure described in Example 1 is followed to prepare a gel of perfluoropolyether concentrated to 99% by volume, using the following components:
  • Example 2 The procedure described in Example 1 is followed to prepare a gel of Perfluoropolyether concentrated to 95% by volume, using the following components:
  • Example 2 The procedure described in Example 1 is followed, to prepare a gel of perfluoropolyether concentrated to 99% by volume, using the following components:
  • Example 2 The procedure described in Example 1 was followed to prepare a gel of perfluoropolyether concentrated to 95% by volume, using the following components:
  • Example 2 The procedure described in Example 1 was followed to prepare a gel of C 2 F 3 Cl 3 concentrated at 99% by volume, using the following components:
  • Example 7 The gel formulation of Example 7 was tested for adverse effects on normal and scarified skin of 3 rabbits, as follows.
  • a quantity of 0.5 ml of the gel was applied to the skin of the animals for 4 hours with a semi-obstructed dressing. The dressing was then removed and the reactions were noted after 1 hour and every day for 14 days. No irritation was observed on the normal and the scarified skin.
  • Example 21 The procedure of Example 21 was followed using the gel of Example 7 (fluorocarbon 95% v/v, F7AO, 1% w/v, water 5% v/v). No irritation was observed after 14 days.
  • Fluorocarbon % v/v
  • Water % v/v
  • Surfactants % w/v
  • Ratio of Surfactant /Water Viscosity at 0.1s -1 1 perfluorodiisopropyldecalin (99) 1 F7A0 1/5 140.2 0.2 2 perfluorodiisopropyldecalin (97,5) 2.5 F7AO 1/5 83.2 0.5 3 perfluorodiisopropyldecalin (95) 5 F7AO 1/5 56.5 1 4 perfluorodiisopropyldecalin (97,5) 2.5 F7AO 1/3 203.5 0.83 5 perfluorodiisopropyldecalin (90) 10 F7AO 1/3 122.7 3.33 6 perfluorodiisopropyl

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Compositions Of Macromolecular Compounds (AREA)

Abstract

Compositions for topical application in gel form comprising a fluorocarbon or perfluorocarbon compound or mixtures thereof at a concentration of at least about 75% v/v, a minor quantity of a surface active agent and an aqueous phase. The compositions provide a storage-stable high concentration fluorocarbon gel that is prepared without the use of thickeners or additional stabilizing agents. The gels are useful in formulations for pharmaceutical, cosmetic purposes and for other products as well.

Description

The present invention relates to viscoelastic compositions or gels which may have uses in cosmetics, biology, therapeutics and elsewhere, eg as protective creams and lubricating agents. It relates particularly to viscoelastic compositions that have high concentrations of highly fluorinated or perfluorinated compounds.
Fluorocarbons have numerous biomedical applications because of their high chemical and biological inertness and their capacity to dissolve a considerable amount of gases, particularly oxygen, carbon dioxide and air per unit volume. Indeed, at 37°C under a pure oxygen atmosphere, a fluorocarbon can dissolve about 50% of its volume of oxygen.
Background Art
Compositions of fluorocarbons can also be used for the treatment of wounds, for example burns, as described in U.S. Patent 4,366,169. According to this disclosure, the wound is put in contact with a liquid fluorocarbon directly, or indirectly through a dressing, for example a sponge, gauze, foam, dispersion or gel into which the fluorocarbon has been incorporated. However, the '169 patent does not disclose a high concentration fluorocarbon formulation or a procedure for preparing a fluorocarbon-rich gel.
High concentration fluorocarbon formulations can increase the gas-transfer capacity of preparations for topical application, improving their therapeutic effects and protecting the tissues coated therewith. Highly viscous preparations of this type can be easily applied to the wounded tissues.
Fluorocarbons have been used in the form of emulsions or water-rich gels. Known gel formulations contain low concentrations of fluorocarbons and require stabilizing or thickening agents to maintain a desirable consistency. Thus, U.S. Patent No. 5,073,378 describes compositions for the treatment of burns, obtained from solutions of collagen, containing a growth-factor derived from platelets, and a fluorocarbon phase whose perfluorocarbon content is low. U.S. Patent No. 4,917,930 and EP-A-0158996 describe compositions in the form of fluorocarbon emulsions comprising no more than 50% fluorocarbon by weight, or about 25% fluorocarbon by volume. These compositions are obtained by preparing an initial dispersion comprising a fluorocarbon and a surfactant complexed with the fluorocarbon, and then concentrating the fluorocarbon phase of the dispersion, for example by centrifugation, separating the fluorocarbon-rich phase, and redispersing this phase in an aqueous medium optionally containing a surfactant. Although this procedure makes it possible to limit the quantity of surfactant used, it does not provide formulations having fluorocarbon concentrations greater than 50% by weight. The emulsions obtained by this process are intended to be injectable.
U.S. Patent No. 4,569,784 describes a stable gel of fluorocarbon also comprising no more than 50% by volume of fluorocarbon, which requires considerable quantities of surfactant for stabilization. This gel is prepared by a similar complex procedure of concentrating an emulsion by centrifugation, and requires high-pressure apparatus or the use of ultrasound.
FR-A-2 630 347 describes fluorocarbon gels comprising, by contrast with those described in the above patents, a high proportion of water, about 60 to 98% by weight.
WO-A-93/09762 describes the use of fluorocarbon suspensions or emulsions for intravascular applications, containing at most 90 g/100 ml (about 50% v/v).
WO-A-90/15807 describes the use of phosphorus-containing fluorinated surfactants in fluorocarbon emulsions and other compositions containing at most 70% in volume of fluorocarbons.
Obraztsov (poster contribution to the fifth ISBS, San Diego California, USA, March 1993) describes an emulsion prepared from a mixture of fluorocarbons containing perfluorodecalin (80% w/v, 40% v/v), emulsified using a polyoxyethylene/polyoxypropylene copolymer (Proxanol 268) and gelified by 1,2-propyleneglycol. Preliminary studies have shown that this emulsion has a beneficial effect on the speed of cicatrization of burns and surgical wounds (activation of keratinocytes) and should be more efficacious than the biostimulating medicaments traditionally used (methyluracyl and solkoseryl). But the fluorocarbon content of these preparations does not exceed 50% by volume and the gelification is obtained by the use of a non-surfactant diol.
Disclosure of the invention
In one aspect the invention provides a viscoelastic gel composition having an oily phase and an aqueous phase, wherein:
  • (a) the oily phase comprises at least one fluoro-compound, the or each said fluoro-compound being a linear, branched and/or cyclic hydrocarbon (which may be saturated or unsaturated, and which may have one or more heteroatoms interposed in its carbon chain) whereof at least 30% of the hydrogen atoms are replaced by fluorine (and optionally one or more hydrogen atoms are replaced by Br and/or Cl and/or I);
  • (b) said at least one fluoro-compound constitutes 75 to 99.7% (v/v) of the composition;
  • (c) said aqueous phase represents 0.3 to 25% (v/v) of the composition; and
  • (d) said composition includes at least one fluorinated surfactant, optionally together with one or more non-fluorinated surfactants, the total surfactant content being 0.1 to 10% (w/v) of the composition.
    • Embodiments of the present invention may provide compositions comprising highly fluorinated or perfluorinated organic compounds formulated as gels having highly viscoelastic properties. They also provide procedures to gelify fluorocarbon. Certain of these compositions are perfectly transparent. Embodiments may be useful in many applications, but particularly in medicine, pharmacy, cosmetics and in biological applications.
    Preferred compositions, having a higher fluorocarbon concentration than previously known compositions of the same type, are advantageously used as topical applications. Preferred compositions are stable, easily sterilized by heat, and are easy to prepare without requiring thickening by addition of a gelifying agent.
    They may be in the form of a viscoelastic gel, stable and permeable to gases.
    Definitions
    In the description of the invention; unless the context requires otherwise,
  • gel designates a semi-solid, apparently homogenous substance which can have the consistency of gelatin.
  • highly fluorinated or perfluorinated compound designates linear, branched or cyclic hydrocarbons, saturated or unsaturated, or derivatives of these, which are partially or totally fluorinated.
  • perfluorinated designates a totally fluorinated compound.
  • partially fluorinated signifies that at least 30% of the hydrogen atoms of the hydrocarbon or of its derivative have been replaced by fluorine atoms.
  • derivatives are fluorinated compounds, for example, wherein heteroatoms, such as O or S, are inserted into the carbon chain and/or wherein the hydrogen atoms of the hydrocarbon are substituted by Br, Cl or I as well as fluorine.
    • Modes for carrying out the Invention
    The fluorinated organic compound can be chosen, for example, among the fluorocarbons and perfluorinated compounds such as linear, branched, cyclic or polycyclic perfluoroalkanes, perfluoroethers, perfluoropolyethers, perfluoroamines, freons, mixed fluorinated/hydrogenated compounds, perfluoroalkyl bromides or chlorides and mixed derivatives, which can be partially fluorinated and partially hydrogenated. Suitable compounds are perfluorodecalin, 1,2-bis(F-alkyl)ethenes (1,2-bis(F-butyl)ethene, 1-F-isopropyl,2-F-hexylethene and 1,2-bis(F-hexyl)ethene), perfluoromethyldecalin, perfluorodimethyldecalin, perfluoromethyl-, and dimethyladamantane, perfluoromethyl-dimethyl- and trimethylbicyclo (3,3,1) nonane and homologs, perfluoroperhydrophenanthrene, ethers of formulae: (CF3)2CFO(CF2CF2)2OCF(CF3)2, (CF3)2CFO(CF2CF2)3OCF(CF3)2, (CF3)2CFO(CF2CF2)2F, (CF3)2CFO(CF2CF2)3F, F[CF(CF3)CF2O]2CHFCF3, [CF3CF2CF2(CF2)u]2O with u= 1, 3 or 5, amines N(C3F7)3, N(C4F9)3, N(C5F11)3, perfluoro-N-methylperhydroquinoline and perfluoro-N-methylperhydroisoquinoline, perfluoroalkyl hydrides such as C6F13H, C8F17H, C8F16H2 and the halogenated derivatives C6F13Br, C8F17Br (perflubron), C6F13CBr2CH2Br, 1-bromo 4-perfluoroisopropyl cyclohexane, C8F16Br2, CF3O(CF2CF2O)uCF2CH2OH with u=2 or 3. Examples of mixed fluorinated/hydrogenated compounds are C6F13C10H21, C6F13CH=CHC6H13, C8F17CH=CHC8H17. Examples of fluorinated polyethers are CF3[(OCF2CF2)p(OCF2)qCF3' where p/q = 0.6 to 0.7. These compounds can be used alone or in mixtures.
    According to a preferred embodiment, the highly fluorinated or perfluorinated compound used comprises from 2 to 20 carbon atoms, preferably from 6 to 20 carbon atoms and more preferably from 8 to 20 carbon atoms.
    Preferably, according to the invention, the highly fluorinated or perfluorinated compound of the composition has a high boiling point, for example above 140°C, so that its evaporation is slow and it is well adapted to use in the form of a salve or ointment. For applications in which a faster evaporation of a fluorocarbon from a gel is desirable, a fluorocarbon having a lower boiling point can be used.
    Examples of high boiling point fluorocarbon compounds are:
  • perfluoroperhydrophenanthrene (bp 215°C)
  • perfluoroperhydrofluoranthene (bp 240°C)
  • perfluorotributylamine (bp: 178°C)
  • bis(perfluorohexyl)1,2-ethene (bp 195°C)
  • perfluorofluorene (bp 194°C); and APF-215™, APF-240™, APF-260™ (Air Products, USA) (bp 215, 216 and 260°C respectively).
    • Other highly fluorinated compounds useful in the invention are
  • perfluorodiisopropyldecalin
  • perfluoro-n-butyldecalin
  • perfluorodixylylmethane
  • perfluorodixylylethane
  • perfluorooctyl bromide
  • perfluoropolyethers, for example, the fomblins™ of Ausimont of various molecular weights, for examples MW 2500 and 3300,
  • C10F21H
  • C2F3Cl3
    • The surfactants used in the invention can be perfluoroalkylated surfactants alone or in mixtures with one or more hydrogenated surfactants. By "perluoroalkylated" is meant that the surfactant contains a perfluoroalkyl group. Preferably it also contains a (non-fluorinated) alkyl group. The surfactants can be non-ionic, anionic, cationic or zwitterionic or mixtures thereof.
    For applications in the biomedical or cosmetic field, surfactants known by those skilled in the art to be the most biocompatible are used. Accordingly, perfluoroalkylated surfactants are preferred, as they are much more efficacious and less toxic than their hydrocarbon analogs, particularly because they have low hemolytic activity (J.G. Riess et al, Adv. Mat., 3:249-251 (1991).
    For example, compounds of formula I detailed hereafter tolerated at doses up to 1.25g/kg after intravenous injection in mice of a dispersion of these compounds in physiological saline. Compounds of WO-A-91/914689, telomeric amphiphilic surfactants, used in this invention are tolerated up to 4g/kg after intravenous injection in mice of a dispersion of these compounds in physiological saline.
    Examples of suitable perfluoroalkylated surfactants are the amine oxides described in U.S.Patent 3,828,085, in particular those having the formula RF(CH2)nCONH-R1-N(O)R2R3
    ("formula I") wherein
  • RF is a perfluoroalkyl group of from 4 to 12 carbon atoms;
  • R1 is an alkyl group of from 1 to 6 carbon atoms;
  • R2 and R3, which can be identical or different, are selected from the group consisting of alkyl groups of from 1 to 6 carbon atoms or alkyl groups of from 2 to 16 carbon atoms having a hydroxyl terminus; or fluorinated phosphorus derivatives such as those described in WO-A-90/5807, in particular fluorinated derivatives of phosphocholine, or fluorinated telomeric surfactants such as those described in WO-A-91/914689.
    • The quantities of surfactants used in the invention are low (0.1 to 10% w/v) and are chosen in relation with the quantity of aqueous phase used such that the weight ratio of surfactant/aqueous phase is from 1/10 to 1/1, preferably from 1/5 to 1/3.
    The compositions of the invention can be prepared by low-energy mechanical homogenization techniques, in particular, which are far easier to operate than those such as sonication or high-energy homogenization formerly used for the preparation of fluorocarbon gels.
    Thus, the invention provides a procedure for the preparation of the composition of fluorinated organic compounds described above, comprising the steps of:
  • (a) dispersing at least one suitable surfactant in the aqueous phase by mechanical stirring;
  • (b) progressively adding to the dispersion of step (a), under stirring, the required quantity of oily phase fluorocarbon to form a gel of fluorinated compound(s); and optionally
  • (c) degassing the gel of step (b).
    • The degassing can be done for example, by centrifugation at room temperature.
    Using the procedure described, a concentrated gel is obtained without the necessity of an intermediate step of preparing an emulsion which is then concentrated by centrifugation by expensive techniques or thickened as described in the prior art. The preparation of gels is far simpler than that described in U.S. Patent No. 4,569,784 for preparing fluorocarbon emulsions because the techniques of low-energy dispersion are sufficient to form the gels, whereas for the preparation of classical emulsions, mechanical high-pressure homogenizers of the Manton-Gaulin type, or microfluidizer or ultrasound must be used.
    When the composition of the invention is to be used for biomedical applications, the gel can be sterilized; this can be done, for example, by heating in a static autoclave under standard procedures.
    When the composition comprises additives, these can be added to the aqueous phase, the oily phase or to both phases. The additives can be mineral salts, buffers, oncotic and osmotic agents, nutritive agents, active principles, medicinal substances, filters of particular rays, or other ingredients that improve the stability, efficacy and biological tolerance of the compositions.
    The compositions of fluorinated compounds of the invention present characteristics very different from those of known emulsions and fluorocarbon gels. The gels compositions of the invention are often in the form of transparent gels, as compared to the milky emulsions.
    Also, the concentration of perfluorinated compound of the present gel compositions is far higher (75 to 99.7% v/v) than the maximum concentration of up to about 70% (v/v) in known compositions, and the ratio of surfactant to the highly fluorinated or perfluorinated compounds, necessary for the preparation of the composition, is far lower than that used in known compositions.
    The quantity of water which can be incorporated in the gel is variable and can be adapted to the intended application. Indeed, some compositions may contain only 0.3% of water, but others may contain up to 25% (v/v) of water. In the latter case, greater quantities of surfactant are generally used, because for a given concentration of surfactant, the viscosity of the gel is decreased as the quantity of water increases. For a given amount of water, the viscosity can be increased by increasing the proportion of surfactant. A surfactant to aqueous phase ratio of 1/5 generally provides a satisfactory viscosity for many uses.
    Moreover, the preparation of the gels of the invention does not require the addition of a gelifying agent, and these gels can be sterilized by heat under standard conditions, and stored for several months at room temperature, without apparent degradation.
    The compositions of highly fluorinated or perfluorinated compounds of the invention can find numerous applications, in particular in cosmetics and pharmacy as well as in light radiation protective or other barrier creams. Their use in ophthalmology is also contemplated. They can also be used in cutaneous applications for the healing of wounds, burns, and bruises, and for the reduction of hypertrophic scars. Indeed, highly fluorinated or perfluorinated compounds, being both hydrophobic and lipophobic, have the property, when spread over the skin (the wound), of isolating the skin and forming a barrier to all forms of contamination and to dust, while remaining permeable to gas and particularly to oxygen. An efficacious protection can also be obtained with thin films of gel of highly fluorinated or perfluorinated compounds. Moreover, these gels can also contain medicaments, for example growth-factors, antibiotics, nutritive elements or other beneficial substances, for example hydrating agents, which will thus be delivered at the appropriate site. The gels of highly fluorinated or perfluorinated compounds have in addition lubricating properties, improving the slipperiness and reducing friction.
    The compositions of the invention can also be used to realize more complex formulations permitting the simultaneous delivery of hydrophilic and lipophilic drugs.
    The compositions of the invention can also be incorporated into a dressing to be applied on the skin. The term dressing here includes any medical material destined to maintain the gel in contact with the skin and perhaps to apply pressure, for topical treatments in the biomedical or cosmetic field. The gels can be incorporated into or deposited on various supports for other applications.
    The compositions of the invention can also be used in any application related to the particular properties of the compositions and in particular to their highly viscoelastic character, their transparency, their surface active character, their chemical inertness, their permeability to oxygen, and if necessary to those of other additives present in the composition.
    Other characteristics and advantages of the invention will be more clearly seen on reading the following examples, which are illustrative, not limitative.
    Some embodiments of the present invention will now be described in detail using the following examples; however, the methods described therein are broadly applicable, and are not to be understood as limited thereby in any way whatsoever. In the following examples, all temperatures are set forth uncorrected in degrees Celsius.
    EXAMPLES Examples 1 to 7 : Preparation of perfluorodiisopropyldecalin gel (APF-240)™.
    In these examples, pentadecafluoroheptylamidopropyl -dimethylamine oxide (F7AO) according to formula I, is used as a surfactant. The appearance of the gels obtained in Examples 1-7 was unchanged after 1 year of storage at room temperature.
    EXAMPLE 1
    In this example, a high proportion of fluorocarbon (99% v/v) was used. The surfactant F7AO (0.045g, 0.2% w/v) was dispersed by mechanical stirring in water for injectable preparations (0.225g, 1% v/v) at a temperature of 20 to 30°C. A quantity of 22.28ml of perfluorodiisopropyldecalin (44.55g, 99% v/v) was then added under a flow of nitrogen at 20-30°C, while stirring with a mixer, and the stirring was continued for 10 min.
    The gel thus obtained was degassed by centrifugation at 1000 rpm for 15 min at room temperature, then conditioned in 5 ml flasks and sterilized in a static autoclave at 121°C for 15 min under a pressure of 105Pa (105N/m2). The viscosity of the gel at 25°C was determined with a Bohlin CS rheometer (3 ml cells).
    The results obtained are shown in Table I.
    EXAMPLE 2
    The procedure described in Example 1 was followed to prepare a fluorocarbon gel composition, using 0.112g of surfactant F7AO, 0.562g of injectable water and 21.94ml (43.88g) of perfluorodiisopropyldecalin. A gel containing 97.5% v/v of fluorocarbon, 2.5% v/v of water and 0.5% w/v of surfactant was thus obtained. The composition and viscosity of the gel are shown in Table I.
    EXAMPLE 3
    The procedure described in Example 1 was followed starting with 0.225g of surfactant F7AO, 1.125g of injectable water and 21.37ml (42.75g) of perfluorodiisopropyldecalin. The composition and viscosity of the gel are shown in Table I.
    EXAMPLE 4
    The procedure described in Example 1 was followed to prepare a gel using 0.187g of surfactant F7AO, 0.560g of injectable water and 21.94ml (43.88g) of perfluorodiisopropyldecalin.
    The composition and viscosity of the gel are shown in Table I.
    EXAMPLE 5
    The procedure described in Example 1 was followed starting with 0.750g (3.33% w/v) of F7AO, 2.25g (10% v/v) of injectable water and 20.25ml (40.50g, 90% v/v) of perfluorodiisopropyldecalin.
    The composition and viscosity of the gel are shown in Table I.
    EXAMPLE 6
    The procedure described in Example 1 was followed starting with 0.9g (4% w/v) of F7AO, 4.5g (20% w/v) of injectable water and 18.00ml (20% v/v) of perfluorodiisopropyldecalin. The composition and viscosity of the gel are shown in Table I.
    EXAMPLE 7
    The procedure described in Example 1 was followed starting with 0.023 g of F7AO (0.1% w/v), 0.12 g of injectable water (0,1% v/v), and 22.3 ml (99.5% v/v) of perfluorodiisopropyldecalin.
    EXAMPLE 8 Preparation of a gel of perfluoroperhydrophenanthrene and perfluoro n-butyldecalin (APF-215)™.
    A gel of perfluoroperhydrophenanthrene and perfluoro n-butyldecalin at a combined concentration of 99% in volume was prepared following the procedure described in Example 1 but using the following components:
  • Perfluoroperhydrophenanthrene and perfluoro n-butyldecalin: 22.27ml (44.55g)
  • injectable water: 0.225g (1% v/v)
  • surfactant F7AO: 0.045g (0.2 % w/v).
    • The composition and viscosity of the gel are shown in Table I. No modification in the appearance of the gel was seen after one year of storage at room temperature.
    EXAMPLE 9
    A low viscosity gel of perfluoroperhydrophenanthrene* and perfluoro n-butyldecalin at a combined concentration of 90% in volume was prepared following the procedure described in Example 1 but using the following components:
    Figure 00140001
    EXAMPLE 10 Preparation of a gel of bis(perfluorohexyl)1,2-ethene.
    The procedure described in Example 1 was followed to prepare a concentrated gel (99% in volume) of bis(perfluorohexyl)1,2-ethene, using the following components:
  • bis(F-hexyl)1,2-ethene: 22.27ml;
  • injectable water: 0.225g (1% v/v); and
  • surfactant F7AO: 0.045g (0.2% w/v)
    • The composition and viscosity of the gel are shown in Table I. No change in the appearance of the gel obtained in was seen after one year of storage at room temperature.
    EXAMPLES 11 to 13: Preparation of gels of various fluorocarbons concentrated to 95% in volume, using F7AO as surfactant.
    In these examples, various fluorocarbons, and the same proportions of fluorocarbon (95% v/v), water (5% v/v) and surfactant (1% w/v) are used.
    EXAMPLE 11
    The procedure described in Example 1 was followed to prepare a fluorocarbon gel, but using as fluorocarbon APF-260™, i.e. a mixture of perfluorodixylylmethane and perfluorodixylylethane.
    The quantities of fluorocarbon, water and fluorinated surfactant were as follows:
  • fluorocarbon APF-260™: 21.37ml (42.75g)
  • injectable water: 1.125g, and
  • surfactant F7AO: 0.225g.
    • The composition and viscosity of the gel are shown in Table I.
    EXAMPLE 12
    The procedure of Example 1 was used. In addition the mixed fluorocarbon/hydrocarbon compound C6F13C10H21 was dispersed with F7A0 in water.
    Fluorocarbon APF-260 :
    94% v/v
    C6F13C10H21 :
    0.74% v/v
    F7A0 :
    0.82% w/v
    Injectable Water :
    5.26% w/v
    The gel is stable for at least one year.
    EXAMPLE 13
    The procedure described in Example 1 was followed to prepare a gel of perfluorodecalin, using the following components:
  • perfluorodecalin: 21.37ml, 41.46g,
  • injectable water: 1.125g, and
  • surfactant F7AO: 0.225g.
    • The composition and viscosity of the gel are shown in Table I.
    EXAMPLE 14
    A gel of perfluorooctyl bromide was prepared, following the same operation procedure as in Example 1, but using the following components:
  • perfluorooctyl bromide: 21.37ml, 41.03g,
  • injectable water: 1.125g, and
  • surfactant F7AO: 0.225g.
    • The composition and viscosity of the gel are shown in Table I.
    EXAMPLE 15 Preparation of a gel of perfluorooctyl bromide using as surfactant 2-(heptadecafluorooctyl)ethylphosphocholine (F8C2PC)
    The procedure described in Example 1 was followed to prepare this perfluorooctyl bromide gel, using the following components:
  • perfluorooctyl bromide: 21.37ml, 41.03g (95% v/v)
  • injectable water: 1.125g (5% v/v), and
  • surfactant F8C2PC: 0.225g (1% w/v).
    • The composition and viscosity of the gel are shown in Table I.
    EXAMPLES 16 to 19: Preparation of gels of perfluoropolyethers of different molecular weights concentrated to 99 and 95% by volume, using F7AO as surfactant. EXAMPLE 16 Perfluoropolyether (Ausimont, (I-20121 Milan, Italy) Product, MW(aver) = 2500 g) (99% v/v)
    The procedure described in Example 1 is followed to prepare a gel of perfluoropolyether concentrated to 99% by volume, using the following components:
  • perfluoropolyether : 22.27 ml
  • injectable water: 0.225 g (1% v/v)
  • surfactant F7AO: 0.045 g (0.2% w/v)
    • The appearance of the gel obtained was unchanged after 3 months storage at room temperature.
    EXAMPLE 17 Perfluoropolyether (Ausimont Product, MWav = 2500g (95% v/v)
    The procedure described in Example 1 is followed to prepare a gel of Perfluoropolyether concentrated to 95% by volume, using the following components:
  • perfluoropolyether : 21.37 ml
  • injectable water: 1.125 g (5% v/v)
  • surfactant F7AO: 0.225 g (1% w/v)
    • The appearance of the gel remained unchanged after 3 months storage at room temperature.
    EXAMPLE 18 Perfluoropolyether (Ausimont Product, MW = 3300 g) (99% v/v)
    The procedure described in Example 1 is followed, to prepare a gel of perfluoropolyether concentrated to 99% by volume, using the following components:
  • perfluoropolyether : 22.27 ml
  • injectable water: 0.225 g (1% v/v)
  • surfactant F7AO: 0.045 g (0.2% w/v)
    • The appearance of the gel obtained was unchanged after 3 months storage at room temperature.
    EXAMPLE 19 Perfluoropolyether (Ausimont) MWav = 3300 g) (95% v/v)
    The procedure described in Example 1 was followed to prepare a gel of perfluoropolyether concentrated to 95% by volume, using the following components:
  • perfluoropolyether: 21.37 ml
  • injectable water: 1.125 g (5% v/v)
  • surfactant F7AO: 0.225 g (1% w/v)
    • The appearance of the gel obtained was unchanged after 3 months storage at room temperature.
    EXAMPLE 20 Preparation of a gel of C2F3Cl3 at 99% by volume using F7A0 as surfactant.
    The procedure described in Example 1 was followed to prepare a gel of C2F3Cl3 concentrated at 99% by volume, using the following components:
    C2F3Cl3 :
    6.33 ml (99% v/v)
    Injectable Water :
    0.1 ml (1% v/v)
    Surfactant F7A0 :
    0.02 g (0.2% w/v)
    EXAMPLES 21-22: Tolerance of the concentrated fluorocarbon gel EXAMPLE 21
    The gel formulation of Example 7 was tested for adverse effects on normal and scarified skin of 3 rabbits, as follows.
    A quantity of 0.5 ml of the gel was applied to the skin of the animals for 4 hours with a semi-obstructed dressing. The dressing was then removed and the reactions were noted after 1 hour and every day for 14 days.
    No irritation was observed on the normal and the scarified skin.
    EXAMPLE 22
    The procedure of Example 21 was followed using the gel of Example 7 (fluorocarbon 95% v/v, F7AO, 1% w/v, water 5% v/v).
    No irritation was observed after 14 days.
    Examples Fluorocarbon (% v/v) Water (% v/v) Surfactants (% w/v) Ratio of Surfactant /Water Viscosity (Pa.s) at 0.1s-1
    1 perfluorodiisopropyldecalin (99) 1 F7A0 1/5 140.2
    0.2
    2 perfluorodiisopropyldecalin (97,5) 2.5 F7AO 1/5 83.2
    0.5
    3 perfluorodiisopropyldecalin (95) 5 F7AO 1/5 56.5
    1
    4 perfluorodiisopropyldecalin (97,5) 2.5 F7AO 1/3 203.5
    0.83
    5 perfluorodiisopropyldecalin (90) 10 F7AO 1/3 122.7
    3.33
    6 perfluorodiisopropyldecalin (80) 20 F7AO 1/5 57.9
    4
    7 perfluorodiisopropyl decalin (99.5) 0.5 0.1 1/5 _
    8 perfluoroperhydro phenanthrene and perfluoro n-butyldecalin (99) 1 F7AO 1/5 64.07
    0.2
    10 Bis(perfluorohexyl) 1,2-ethene (99) 1 F7AO 1/5 --
    0.2
    11 Perfluorodixylyl methane and perfluorodixylyl ethane (95) 5 F7AO 1/5 --
    1
    13 Perfluorodecalin (95) 5 F7AO 1/5 --
    1
    14 Perfluorooctyl bromide (95) 5 F7AO 1/5 --
    1
    15 Perfluorooctyl bromide (95) 5 F8C2PC 1/5
    1

    Claims (21)

    1. A viscoelastic gel composition having an oily phase and an aqueous phase, wherein,:
      (a) the oily phase comprises at least one fluoro-compound, the or each said fluoro-compound being a linear, branched and/or cyclic hydrocarbon (which may be saturated or unsaturated, and which may have one or more heteroatoms interposed in its carbon chain) whereof at least 30% of the hydrogen atoms are replaced by fluorine (and optionally one or more hydrogen atoms are replaced by Br and/or Cl and/or I);
      (b) said at least one fluoro-compound constitutes 75 to 99.7% (v/v) of the composition;
      (c) said aqueous phase represents 0.3 to 25% (v/v) of the composition; and
      (d) said composition includes at least one fluorinated surfactant, optionally together with one or more non-fluorinated surfactants, the total surfactant content being 0.1 to 10% (w/v) of the composition.
    2. A composition according to claim 1 wherein said at least one fluoro-compound comprises a perfluorinated compound.
    3. A composition according to claim 1 or 2 wherein the at least one fluoro-compound represents at least 80% v/v of the composition.
    4. A composition according to Claim 1 or 2, wherein the at least one fluoro-compound represents at least 90% v/v of the composition.
    5. A composition according to any preceding claim wherein the at least one fluoro-compound has from 2 to 20 carbon atoms.
    6. A composition according to any preceding Claim wherein the fluoro-compound is one or more selected from: perfluoroperhydrofluoranthrene; perfluorooctyl bromide; one or more perfluoropolyethers; perfluorodecalin; perfluoroperhydrophenanthrene; bis(perfluoro-hexyl)-1,2-ethene; a mixture of perfluorodixylylmethane and perfluorodixylylethane optionally together with C6 F13 C10 H21; perfluoroisopropyldecalin; a mixture of perfluoroperhydrophenanthrene and perfluoro n-butyl decalin; and C2 F3 Cl3.
    7. A composition according to any preceding claim wherein the at least one fluoro-compound has a boiling point above 140°C.
    8. A composition according to any of claims 1 to 7, wherein the surfactant is an amine oxide corresponding to the formula RF(CH2)n-CONH-R1N(O)R2R3
      wherein
      RF is a perfluoroalkyl group having from 4 to 12 carbon atoms;
      R1 is an alkyl group having from 1 to 6 carbon atoms;
      R2 and R3, which can be identical or different, are selected from alkyl groups having from 1 to 6 carbon atoms and alkyl groups having from 2 to 16 carbon atoms and having terminal hydroxyl groups; and n = 0 to 12.
    9. A composition according to any preceding claim, wherein the surfactant is or includes pentadecafluoroheptylamidopropyldimethylamine.
    10. A composition according to any of claims 1-9 wherein at least one surfactant is a fluorinated substituted phosphocholine.
    11. A composition according to Claim 10, wherein the surfactant is or includes 2-(heptadecafluorooctyl)ethylphosphocholine
    12. A composition according to any preceding claim wherein the surfactant is or includes at least one fluorinated telomer.
    13. A composition according to claim 12 wherein said telomer comprises
      Figure 00240001
    14. A composition according to any preceding claim wherein the weight ratio of surfactant/aqueous phase is from 1/10 to 1/1.
    15. A composition according to Claim 14 wherein the weight ratio of surfactant/aqueous phase is from 1/5 to 1/3.
    16. A composition according to any preceding claim further comprising at least one additional substance present in either the aqueous or the oily phase or in each of the two phases, wherein the additive substance is selected from nutritive agents, medicinal substances, mineral salts, oncotic agents, osmotic agents, buffers and radiation filters.
    17. A method for preparing a composition according to any preceding claim comprising the steps of:
      (a) dispersing at least one surfactant in an aqueous phase by mechanical stirring, and
      (b) adding to this dispersion a quantity of oily phase, comprising at least one fluoro compound as defined in claim 1 or in an amount sufficient to form a gel.
    18. A method according to claim 17 further comprising heat sterilization of the gel of step (b).
    19. A medical device comprising a composition according to any of claim 1 to 16.
    20. A composition according to any of claims 1-16 for use in topically treating the skin of a mammal by a method comprising applying the composition to the skin.
    21. A pharmaceutical or cosmetic or barrier product comprising a fluorocarbon composition according to any of claims 1 to 16.
    EP94929508A 1993-10-04 1994-10-01 Viscoelastic compositions of fluorinated organic compounds Expired - Lifetime EP0722313B1 (en)

    Applications Claiming Priority (3)

    Application Number Priority Date Filing Date Title
    FR9311786A FR2710840B1 (en) 1993-10-04 1993-10-04 Viscoelastic compositions highly concentrated in fluorinated compounds, their preparation and their uses in the medical and cosmetic fields.
    FR9311786 1993-10-04
    PCT/EP1994/003276 WO1995009606A1 (en) 1993-10-04 1994-10-01 Viscoelastic compositions of fluorinated organic compounds

    Publications (2)

    Publication Number Publication Date
    EP0722313A1 EP0722313A1 (en) 1996-07-24
    EP0722313B1 true EP0722313B1 (en) 1999-05-12

    Family

    ID=9451507

    Family Applications (1)

    Application Number Title Priority Date Filing Date
    EP94929508A Expired - Lifetime EP0722313B1 (en) 1993-10-04 1994-10-01 Viscoelastic compositions of fluorinated organic compounds

    Country Status (12)

    Country Link
    US (1) US5573757A (en)
    EP (1) EP0722313B1 (en)
    JP (1) JPH09503802A (en)
    AT (1) ATE179884T1 (en)
    AU (1) AU688800B2 (en)
    CA (1) CA2173321A1 (en)
    DE (1) DE69418468T2 (en)
    DK (1) DK0722313T3 (en)
    ES (1) ES2134359T3 (en)
    FR (1) FR2710840B1 (en)
    GR (1) GR3030528T3 (en)
    WO (1) WO1995009606A1 (en)

    Families Citing this family (28)

    * Cited by examiner, † Cited by third party
    Publication number Priority date Publication date Assignee Title
    FR2737135B1 (en) * 1995-07-24 1997-09-12 Atta FLUORINATED CONTINUOUS PHASE REVERSE GELS
    FR2737972B1 (en) * 1995-08-24 1997-09-26 Oreal EMULSION HAVING AN AIRY TEXTURE
    US5733526A (en) * 1995-12-14 1998-03-31 Alliance Pharmaceutical Corp. Hydrocarbon oil/fluorochemical preparations and methods of use
    US5980936A (en) * 1997-08-07 1999-11-09 Alliance Pharmaceutical Corp. Multiple emulsions comprising a hydrophobic continuous phase
    DE19926889B4 (en) * 1999-06-12 2005-06-16 Bausch & Lomb Inc. Use of a gel with polyaphron structure for the manufacture of an implant
    DE19938668B4 (en) * 1999-08-14 2006-01-26 Bausch & Lomb Inc. Artificial tears
    AU2000279747A1 (en) * 2000-07-20 2002-02-05 Otkrytoe Aktsionernoe Obschestvo Nauchno-Proizvodstvennaya Firma "Perftoran" Emulsion of perfluororganic compounds for medical purposes, method for producingsaid emulsion and methods for curing and preventing diseases with the aid of the emulsion
    KR20030051680A (en) 2000-09-26 2003-06-25 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 Phosphate fluorosurfactants for use in carbon dioxide
    US7357937B2 (en) * 2002-09-24 2008-04-15 Therox, Inc. Perfluorocarbon emulsions with non-fluorinated surfactants
    EP1684716A4 (en) * 2003-11-05 2009-04-22 Univ Australian Dispersions and methods of preparing them
    DE10358306B8 (en) 2003-12-08 2005-03-03 Coty B.V. Cosmetic and dermatological oxygen carrier system, process for its preparation and its use
    US20060257457A1 (en) * 2004-10-20 2006-11-16 Gorman Anne J Method for making a reinforced absorbable multilayered hemostatic wound dressing
    EP2837393A1 (en) * 2004-10-20 2015-02-18 Ethicon, Inc. Absorbable hemostat
    US9358318B2 (en) * 2004-10-20 2016-06-07 Ethicon, Inc. Method of making a reinforced absorbable multilayered hemostatic wound dressing
    AR054805A1 (en) * 2005-06-29 2007-07-18 Stiefel Laboratories TOPICAL COMPOSITIONS FOR SKIN TREATMENT
    JP4902162B2 (en) * 2005-09-26 2012-03-21 日油株式会社 COMPOSITE MATERIAL MOLDED AND MANUFACTURING METHOD
    EP1776960B1 (en) * 2005-10-20 2009-03-18 Filippo Ernestino Parodi Use of collagen in combination with oxygen- and ozone-releasing perfluorocarbons for the preparation of a medicament for the treatment of skin lesions
    US9107844B2 (en) 2006-02-03 2015-08-18 Stiefel Laboratories Inc. Topical skin treating compositions
    BRPI0709674A2 (en) 2006-03-31 2011-12-06 Stiefel Res Australia Pty Ltd sparkling suspension gel
    EP1970048A1 (en) * 2007-03-15 2008-09-17 Drug Delivery Solutions Limited Polyaphron topical composition with vitamin D
    US10265265B2 (en) * 2007-03-15 2019-04-23 Drug Delivery Solutions Limited Topical composition
    EP2008651A1 (en) 2007-06-26 2008-12-31 Drug Delivery Solutions Limited A bioerodible patch
    JP5142267B2 (en) * 2008-03-04 2013-02-13 独立行政法人産業技術総合研究所 Short chain amphoteric surfactant
    US8343515B2 (en) * 2008-11-25 2013-01-01 Oxygen Biotherapeutics, Inc. Perfluorocarbon gel formulations
    BR112013023458B1 (en) 2011-03-14 2020-04-07 Drug Delivery Solutions Ltd ophthalmic composition, and method for making the ophthalmic composition
    GB201701583D0 (en) 2017-01-31 2017-03-15 Drug Delivery Solutions Ltd Topical composition
    EP3542788A1 (en) 2018-03-19 2019-09-25 MC2 Therapeutics Limited Topical composition comprising calcipotriol and betamethasone dipropionate
    WO2020025910A1 (en) 2018-07-31 2020-02-06 Drug Delivery Solutions Limited Topical composition

    Family Cites Families (12)

    * Cited by examiner, † Cited by third party
    Publication number Priority date Publication date Assignee Title
    EP0031353B1 (en) * 1979-06-25 1984-08-08 Suntech, Inc. Use of perfluorocarbon as burn treatment
    US4569784A (en) * 1980-11-17 1986-02-11 Adamantech, Inc. Preparation of a gel having gas transporting capability
    US4423077A (en) * 1982-07-27 1983-12-27 The University Of Pennsylvania Perfluorochemical emulsion artificial blood
    CA1257828A (en) * 1984-04-16 1989-07-25 William Mccormick Perfluoro compound dispersions containing reduced amounts of surfactant and process of preparation
    US4917930A (en) * 1984-04-16 1990-04-17 Adamantech, Inc. Perfluoro compound dispersions containing reduced amounts of surfactant and process of preparation
    IL84911A (en) * 1987-12-22 1993-04-04 Yissum Res Dev Co Processes for the preparation of collagen products, and pharmaceutical compositions containing the same
    FR2630347B1 (en) * 1988-04-20 1991-08-30 Inst Nat Rech Chimique ISOTROPIC VISCOELASTIC MATERIALS BASED ON WATER, FLUORINATED SURFACTANTS AND FLUORINATED OILS, THEIR PROCESS FOR OBTAINING AND THEIR APPLICATIONS IN VARIOUS AREAS, SUCH AS OPTICS, PHARMACOLOGY AND ELECTRODYNAMICS
    US5185099A (en) * 1988-04-20 1993-02-09 Institut National De Recherche Chimique Appliquee Visco-elastic, isotropic materials based on water, fluorinate sufactants and fluorinated oils, process for their preparation, and their use in various fields, such as optics, pharmacology and electrodynamics
    ES2060184T3 (en) * 1989-06-22 1994-11-16 Atta AMPHYPHILIC MOLECULES CONTAINING FLUORINE AND PHOSPHORUS WITH TENSOACTIVE PROPERTIES.
    FR2679150A1 (en) * 1991-07-17 1993-01-22 Atta PREPARATIONS CONSISTING OF A FLUOROCARBIDE OR HIGHLY FLUORINE COMPOUND AND A LIPOPHILIC-FLUOROPHILIC ORGANIC COMPOUND, AND THEIR USES.
    US5264220A (en) * 1991-11-12 1993-11-23 Long David M Jr Method of extending the vascular dwell-time of particulate therapeutic and particulate diagnostic agents
    US5304325A (en) * 1991-11-13 1994-04-19 Hemagen/Pfc Emulsions containing alkyl- or alkylglycerophosphoryl choline surfactants and methods of use

    Also Published As

    Publication number Publication date
    AU688800B2 (en) 1998-03-19
    EP0722313A1 (en) 1996-07-24
    JPH09503802A (en) 1997-04-15
    FR2710840B1 (en) 1995-12-01
    ATE179884T1 (en) 1999-05-15
    DE69418468D1 (en) 1999-06-17
    DK0722313T3 (en) 1999-11-15
    US5573757A (en) 1996-11-12
    FR2710840A1 (en) 1995-04-14
    CA2173321A1 (en) 1995-04-13
    ES2134359T3 (en) 1999-10-01
    GR3030528T3 (en) 1999-10-29
    DE69418468T2 (en) 1999-10-07
    WO1995009606A1 (en) 1995-04-13
    AU7854194A (en) 1995-05-01

    Similar Documents

    Publication Publication Date Title
    EP0722313B1 (en) Viscoelastic compositions of fluorinated organic compounds
    EP1545757B1 (en) Perfluorocarbon emulsions with non-fluorinated surfactants
    AU669117B2 (en) Preparations comprising a fluorocarbon and a lipophilic/fluorophilic organic compound, and their uses
    US5686102A (en) Pharmacological composition for topical administration
    US3767788A (en) Ophthalmic solution
    US5980936A (en) Multiple emulsions comprising a hydrophobic continuous phase
    EP1996170A2 (en) Silicone based emulsions for topical drug delivery
    EP1982697A1 (en) Emulsion lotion
    WO1998005301A1 (en) Multiple emulsions comprising a hydrophobic continuous phase
    EP0784468A1 (en) Phospholipid- and cholesterol-free aqueous composition for topical application to the skin
    AU717321B2 (en) Reverse gels comprising a continuous fluorinated phase
    JPS6342601B2 (en)
    HUT68858A (en) Topical application composition
    JP2001354520A (en) Laminar silicate-containing w/o/w type and w/o type emulsion
    JP2024114984A (en) Emulsion composition
    WO1993016720A1 (en) Inhibition of bacterial endotoxin
    JP2001300287A (en) Perfluorocarbon emulsifying preparation

    Legal Events

    Date Code Title Description
    PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

    Free format text: ORIGINAL CODE: 0009012

    17P Request for examination filed

    Effective date: 19960429

    AK Designated contracting states

    Kind code of ref document: A1

    Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

    17Q First examination report despatched

    Effective date: 19970728

    GRAG Despatch of communication of intention to grant

    Free format text: ORIGINAL CODE: EPIDOS AGRA

    GRAG Despatch of communication of intention to grant

    Free format text: ORIGINAL CODE: EPIDOS AGRA

    GRAG Despatch of communication of intention to grant

    Free format text: ORIGINAL CODE: EPIDOS AGRA

    GRAH Despatch of communication of intention to grant a patent

    Free format text: ORIGINAL CODE: EPIDOS IGRA

    GRAH Despatch of communication of intention to grant a patent

    Free format text: ORIGINAL CODE: EPIDOS IGRA

    GRAA (expected) grant

    Free format text: ORIGINAL CODE: 0009210

    AK Designated contracting states

    Kind code of ref document: B1

    Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

    REF Corresponds to:

    Ref document number: 179884

    Country of ref document: AT

    Date of ref document: 19990515

    Kind code of ref document: T

    REG Reference to a national code

    Ref country code: CH

    Ref legal event code: EP

    REG Reference to a national code

    Ref country code: IE

    Ref legal event code: FG4D

    REF Corresponds to:

    Ref document number: 69418468

    Country of ref document: DE

    Date of ref document: 19990617

    ITF It: translation for a ep patent filed
    ET Fr: translation filed
    REG Reference to a national code

    Ref country code: ES

    Ref legal event code: FG2A

    Ref document number: 2134359

    Country of ref document: ES

    Kind code of ref document: T3

    REG Reference to a national code

    Ref country code: PT

    Ref legal event code: SC4A

    Free format text: AVAILABILITY OF NATIONAL TRANSLATION

    Effective date: 19990715

    REG Reference to a national code

    Ref country code: DK

    Ref legal event code: T3

    PLBE No opposition filed within time limit

    Free format text: ORIGINAL CODE: 0009261

    STAA Information on the status of an ep patent application or granted ep patent

    Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

    26N No opposition filed
    PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

    Ref country code: FR

    Payment date: 20000911

    Year of fee payment: 7

    Ref country code: AT

    Payment date: 20000911

    Year of fee payment: 7

    PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

    Ref country code: DK

    Payment date: 20000912

    Year of fee payment: 7

    PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

    Ref country code: IE

    Payment date: 20000915

    Year of fee payment: 7

    PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

    Ref country code: GB

    Payment date: 20000919

    Year of fee payment: 7

    PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

    Ref country code: SE

    Payment date: 20000920

    Year of fee payment: 7

    Ref country code: MC

    Payment date: 20000920

    Year of fee payment: 7

    PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

    Ref country code: PT

    Payment date: 20000921

    Year of fee payment: 7

    Ref country code: CH

    Payment date: 20000921

    Year of fee payment: 7

    PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

    Ref country code: NL

    Payment date: 20000925

    Year of fee payment: 7

    Ref country code: DE

    Payment date: 20000925

    Year of fee payment: 7

    PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

    Ref country code: LU

    Payment date: 20001004

    Year of fee payment: 7

    PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

    Ref country code: ES

    Payment date: 20001010

    Year of fee payment: 7

    PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

    Ref country code: BE

    Payment date: 20001016

    Year of fee payment: 7

    PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

    Ref country code: GR

    Payment date: 20001023

    Year of fee payment: 7

    PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

    Ref country code: MC

    Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

    Effective date: 20011001

    Ref country code: LU

    Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

    Effective date: 20011001

    Ref country code: IE

    Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

    Effective date: 20011001

    Ref country code: GB

    Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

    Effective date: 20011001

    Ref country code: DK

    Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

    Effective date: 20011001

    Ref country code: AT

    Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

    Effective date: 20011001

    PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

    Ref country code: SE

    Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

    Effective date: 20011002

    Ref country code: ES

    Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

    Effective date: 20011002

    PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

    Ref country code: LI

    Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

    Effective date: 20011031

    Ref country code: GR

    Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

    Effective date: 20011031

    Ref country code: CH

    Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

    Effective date: 20011031

    Ref country code: BE

    Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

    Effective date: 20011031

    REG Reference to a national code

    Ref country code: GB

    Ref legal event code: IF02

    BERE Be: lapsed

    Owner name: ALLIANCE PHARMACEUTICAL CORP.

    Effective date: 20011031

    PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

    Ref country code: PT

    Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

    Effective date: 20020430

    PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

    Ref country code: NL

    Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

    Effective date: 20020501

    GBPC Gb: european patent ceased through non-payment of renewal fee

    Effective date: 20011001

    EUG Se: european patent has lapsed

    Ref document number: 94929508.3

    REG Reference to a national code

    Ref country code: DK

    Ref legal event code: EBP

    REG Reference to a national code

    Ref country code: CH

    Ref legal event code: PL

    PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

    Ref country code: FR

    Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

    Effective date: 20020628

    NLV4 Nl: lapsed or anulled due to non-payment of the annual fee

    Effective date: 20020501

    PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

    Ref country code: DE

    Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

    Effective date: 20020702

    REG Reference to a national code

    Ref country code: IE

    Ref legal event code: MM4A

    REG Reference to a national code

    Ref country code: FR

    Ref legal event code: ST

    REG Reference to a national code

    Ref country code: PT

    Ref legal event code: MM4A

    Free format text: LAPSE DUE TO NON-PAYMENT OF FEES

    Effective date: 20020430

    REG Reference to a national code

    Ref country code: ES

    Ref legal event code: FD2A

    Effective date: 20021113

    PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

    Ref country code: IT

    Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED.

    Effective date: 20051001